GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exicure Inc (NAS:XCUR) » Definitions » Cash Flow from Financing

Exicure (Exicure) Cash Flow from Financing : $3.68 Mil (TTM As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Exicure Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2023, Exicure paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Exicure spent $0.00 Mil on financial activities for the three months ended in Sep. 2023.


Exicure Cash Flow from Financing Historical Data

The historical data trend for Exicure's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exicure Cash Flow from Financing Chart

Exicure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Financing
Get a 7-Day Free Trial 20.09 84.31 15.13 1.12 -3.11

Exicure Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 4.60 -0.92 -

Exicure Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Exicure's Cash from Financing for the fiscal year that ended in Dec. 2022 is calculated as:

Exicure's Cash from Financing for the quarter that ended in Sep. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Exicure  (NAS:XCUR) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Exicure's issuance of stock for the three months ended in Sep. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Exicure's repurchase of stock for the three months ended in Sep. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Exicure's net issuance of debt for the three months ended in Sep. 2023 was $0.00 Mil. Exicure received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Exicure's net issuance of preferred for the three months ended in Sep. 2023 was $0.00 Mil. Exicure paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Exicure's cash flow for dividends for the three months ended in Sep. 2023 was $0.00 Mil. Exicure received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Exicure's other financing for the three months ended in Sep. 2023 was $0.00 Mil. Exicure received $0.00 Mil on other financial activities.


Exicure Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Exicure's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Exicure (Exicure) Business Description

Traded in Other Exchanges
Address
2430 N. Halsted Street, Suite 410, Chicago, IL, USA, 60614
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Executives
Minhee Eom director 2430 N. HALSTED ST., CHICAGO IL 60614
Dongho Lee director 2430 N. HALSTED ST., CHICAGO IL 60614
Hyuk Joon Ko director 2430 N. HALSTED ST., CHICAGO IL 60614
Hojoon Lee director 2430 N. HALSTED ST., CHICAGO IL 60614
Dgp Co., Ltd. 10 percent owner 23, GEURINTEKEU-RO, YEONGGWANG-EUP, YEONGGWANG-GUN, JEOLLANAM-DO M5 57024
Jung Sang Kim director, officer: Chief Executive Officer, CFO 46-31 CHEONGRO 3 GIL, GEUMSUNG-MYEON, UEISUNG-GUN, GYEONGSANGBUK-DO M5 37357
Josh Miller director, officer: Chief Executive Officer, CFO 2430 N. HALSTED ST., CHICAGO IL 60614
Jiyoung Hwang director C/O EXICURE, INC., 2430 N. HALSTED ST., CHICAGO IL 60614
Cheolho Jo director 2430 N. HALSTED ST., CHICAGO IL 60614
Seung Soo Shin director 2430 N. HALSTED ST., CHICAGO IL 60614
Hyukku Lee director 2430 N. HALSTED ST., CHICAGO IL 60614
Sung Uh Kang Paul director 2430 N. HALSTED ST., CHICAGO IL 60614
Changil Ahn director 2430 N. HALSTED ST., CHICAGO IL 60614
Cbi Usa, Inc. 10 percent owner 3000 WESTERN AVENUE, SUITE 400, SEATTLE WA 98121
Bali Muralidhar director C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077

Exicure (Exicure) Headlines

From GuruFocus

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

By Business Wire Business Wire 05-27-2022

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

By Business Wire Business Wire 05-04-2023